Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19307218 | 1.00 | RAB9A (0.47) | RAB9AMAPTNPC1KMT2AIMPDH2 | |
| SCHEMBL29614871 | 0.87 | IMPDH2 (0.42) | RAB9AMAPTNPC1KMT2AIMPDH2 | |
| SCHEMBL19307104 | 0.87 | IMPDH2 (0.42) | RAB9AMAPTNPC1KMT2AIMPDH2 | |
| SCHEMBL29614706 | 0.87 | KDM4E (0.53) | RAB9AMAPTNPC1KMT2AIMPDH2 | |
| SCHEMBL19307111 | 0.87 | KDM4E (0.53) | RAB9AMAPTNPC1KMT2AIMPDH2 | |
| SCHEMBL29614729 | 0.86 | IMPDH2 (0.54) | RAB9AMAPTNPC1KMT2AIMPDH2 | |
| SCHEMBL19307170 | 0.86 | IMPDH2 (0.54) | RAB9AMAPTNPC1KMT2AIMPDH2 | |
| SCHEMBL29614804 | 0.84 | F10 (0.40) | IMPDH2GSK3B | |
| SCHEMBL19307230 | 0.80 | IMPDH2 (0.55) | IMPDH2ROCK1HTT | |
| SCHEMBL29614770 | 0.80 | IMPDH2 (0.55) | IMPDH2ROCK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | CORNELL UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | PTGES, PTGS1, PTGES2 | RAB9A 3843/4885MAPT 4843/4885NPC1 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.